Guidance Document: Regulatory Requirements for Drug Identification Numbers (DINs) - Summary
Related guides and help
Related acts and regulations
From Health Canada
Overview
This guidance document provides:
- assistance on the interpretation of the regulatory requirements associated with a DIN
- guidance to manufacturers on their obligation to accurately report to Health Canada the following notifications for a change of drug status within the required timelines:
- Market notification
- 12 months without sale notification
- Discontinuation of sale notification
In this guide
- 1. Introduction
- 2. Purpose
- 3. Scope
- 4. Policy objectives
- 5. Definitions
- 6. Guidance for implementation
- 6.1 DIN assignment
- 6.2 Drug statuses and the Drug Product Database
- 6.3 Market notification
- 6.4 Twelve months without sale notification - dormant status
- 6.5 Discontinuation of sale notification
- 6.6 DIN cancellation
- 6.6.1 Cancellation due to safety issue
- 6.6.2 Cancellation due to failure to provide annual drug notification - C.01.014.6 (2) (a) of the Food and Drug Regulations
- 6.6.3 Cancellation as product is not a drug - C.01.014.6 (1) (c) of the Food and Drug Regulations
- 6.6.4 Cancellation due to a transition under the Biocides Regulations
- 6.7 Required activities following the cancellation of a DIN
- 6.8 Reassignment of a DIN by Health Canada
- 6.9 Commercial exportation
- 6.10 Submitting notifications to Health Canada
- 6.11 Contact us
- Appendix A Template email - Request for DIN reassignment
View complete guide
Download PDF (700 KB, 31 pages)
Details and history
Administrative changes date: February 18, 2025
Published: May 3, 2019
Consulted: January 25, 2019
Part of topic: Guidance on legislation
For assistance
Our service hours are Monday to Friday from 8 a.m. to 6 p.m. (local time) and closed statuary holidays.
Contact us by email:
Page details
- Date modified: